AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21415046
Drug: Stepped-care approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care approach starting with supervised self-help, with fluoxetine added if non-responders after 6 sessions, followed by CBT if needed
Trial: 14716714
Drug: Glucose (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (four 3 mg dextrose tablets)
Trial: 14716714
Drug: Placebo (sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sorbitol tablets)
Trial: 9581743
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg IV infusion, two 10-min infusions)
Trial: 9581743
Drug: Procainamide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (400 mg IV infusion, three successive 10-min infusions)
Trial: 16963472
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg/day
Trial: 18950770
Drug: Perindopril 8
RxNorm normalized name: perindopril 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 8 mg/day
Trial: 1937372
Drug: Ranitidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (400 mg b.i.d.)
Trial: 23785050
Drug: Enoxaparin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 40 mg once daily for 7 days in low-risk group.
Trial: 23785050
Drug: Enoxaparin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 1 mg/kg subcutaneously 2 times a day for 48 hours, then 40 mg once daily for 5 days in high-risk group.
Trial: 21899708
Drug: 2.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% lidocaine plus 2.5% prilocaine cream (n = 46)
Trial: 18779616
Drug: Clodronate, 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate, 1.6 g orally administered daily
Trial: 29766635
Drug: MK-1293 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1293 insulin glargine (Mk-Gla; 100 U/mL)
Trial: 29766635
Drug: Originator insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Originator insulin glargine (Lantus; Sa-Gla)
Trial: 29761615
Drug: MK-1293 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1293 insulin glargine (Mk-Gla)
Trial: 24910399
Drug: Knee stabilization
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee stabilization therapy prior to strength/functional training
Trial: 24910399
Drug: Control programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control programme (without knee stabilization therapy)
Trial: 8288727
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg bid)
Trial: 11720425
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no further treatment)
Trial: 27486878
Drug: PF induction
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF induction chemotherapy
Trial: 24962480
Drug: Oligonol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligonol (200 mg daily for 1 week)
Trial: 21167471
Drug: Tinidazole 500
RxNorm normalized name: tinidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 500 mg twice daily
Trial: 21167471
Drug: Tinidazole 1
RxNorm normalized name: tinidazole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 1 g twice daily
Trial: 11719823
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized estradiol substitution (Group I)
Trial: 16715674
Drug: 24 g
RxNorm normalized name: glucose 24 g/31 g oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g iodine
Trial: 16715674
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g iodine
Trial: 8299830
Drug: Computed radiography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computed radiography with a photostimulable storage phosphor (50% radiation dose)
Trial: 8299830
Drug: Computed radiography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computed radiography with a photostimulable storage phosphor (10% radiation dose)
Trial: 8299830
Drug: Conventional calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional calcium tungstate screen‐film combination (100% radiation dose)
Trial: 27559716
Drug: ω‐3 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 plus capsules
Trial: 20077006
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment (ACT) without IMR
Trial: 19202956
Drug: Long-acting β-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β-agonists (LABAs) with inhaled corticosteroid (ICS)
Trial: 12672582
Drug: Chloramphenicol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (75 mg/kg per day, max 2 g/day, in four doses for 14 days)
Trial: 1514339
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg/kg
Trial: 1992843
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered nicotine
Trial: 31916033
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with immediate provisionalization (TG)
Trial: 31916033
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) with immediate implants with intact alveoli
Trial: 22623016
Drug: Tramadol (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (350 mg)
Trial: 22623016
Drug: Hydromorphone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (16 mg)
Trial: 15747762
Drug: Early retinal
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early retinal ablative treatment
Trial: 11709366
Drug: Amprenavir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir with saquinavir soft gel capsule
Trial: 9046304
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg per day tirilazad
Trial: 9046304
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg per day tirilazad
Trial: 9046304
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including placebo and both doses of tirilazad)
Trial: 28302543
Drug: Pidotimod (PDT)
RxNorm normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod (PDT) 800mg, 2 daily doses
Trial: 28302543
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg b.i.d. alone
Trial: 21701222
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days
Trial: 2112166
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin ethylsuccinate
Trial: 15080578
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg every 12 hours for 7 days)
Trial: 15080578
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg every 12 hours for 7 days)
Trial: 9824784
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 80 mg/m2 by infusion over 2 hours
Trial: 9824784
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 80 mg/m2 by infusion over 3.5 hours
Trial: 9824784
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 80 mg/m2 by infusion over 4 hours
Trial: 9824784
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) pharmacodynamics
Trial: 9824784
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) pharmacokinetics
Trial: 8948268
Drug: L-thyroxine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine (100 micrograms/day)
Trial: 16394754
Drug: Dynamic extensor
RxNorm normalized name: Wolfiporia extensa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic extensor brace treatment for 12 weeks (Group 1; n = 30)
Trial: 16394754
Drug: No brace
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No brace treatment (Group 2; n = 33)
Trial: 28926170
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg plus metformin
Trial: 28926170
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg plus placebo
Trial: 23802840
Drug: Saxagliptin plus
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin plus metformin
Trial: 28406090
Drug: 2 evogliptin/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 evogliptin/metformin XR 2.5/500 mg FDC tablets
Trial: 28406090
Drug: Separate formulations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulations of evogliptin 5 mg and metformin XR 1,000 mg
Trial: 23815302
Drug: 2-dose alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-dose alemtuzumab (15 mg at day 0 and 15 mg repeated on day 7)
Trial: 16940830
Drug: Once-daily amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily amoxicillin (750 mg or 1000 mg) for 10 days
Trial: 16940830
Drug: Twice-daily amoxicillin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily amoxicillin (2 doses of 375 mg or 500 mg) for 10 days
Trial: 16940830
Drug: Once-daily amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily amoxicillin
Trial: 15473127
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose sulfonylurea (Glimepiride 8 patients, gliclazide 5 patients)
Trial: 15473127
Drug: Repaglinide 2
RxNorm normalized name: repaglinide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 2 x 2 mg
Trial: 11015795
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (n = 595 in 1997-1998; n = 587 in 1998-1999)
Trial: 6547072
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (Adriamycin 25 mg/m2, cyclophosphamide 700 mg/m2, vincristine 1.5 mg/m2, arabinosylcytosine 100 mg/m2, methotrexate 10 mg/m2, prednisone 60 mg/m2) and radiotherapy (2000 rad)
Trial: 49984
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy and radiotherapy
Trial: 11903513
Drug: Piribedil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (3 mg)
Trial: 9874055
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of antihypertensive medication
Trial: 9874055
Drug: Nonpharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic therapy (weight loss and/or sodium reduction)
Trial: 9139386
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg twice daily for 5 days)
Trial: 6789354
Drug: Flurazepam 15
RxNorm normalized name: flurazepam 15 mg oral capsule
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurazepam 15 mg
Trial: 29723341
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication counseling session at discharge.
Trial: 24563084
Drug: LIS (nutraceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIS (nutraceutical product containing Garcinia cambogia, l-carnitine, and Ascophyllum nodosum)
Trial: 20662896
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 800 mg once daily
Trial: 17717534
Drug: HFCS (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCS (50 g)
Trial: 17717534
Drug: Sucromalt (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucromalt (80 g)
Trial: 17717534
Drug: HFCS (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCS (80 g)
Trial: 17717534
Drug: Fructose/glucose blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose/glucose blend (56 g) + inulin (24 g)
Trial: 19605831
Drug: Capsule endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule endoscopy
Trial: 10483964
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil (240 mg/day) initiated three days before cardioversion and continued during follow-up (group II)
Trial: 8758387
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.4 mg/ml used in trabeculectomy
Trial: 19746201
Drug: Intradetrusor injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor injections of botulinum toxin‐A (BTX‐A)
Trial: 7520188
Drug: Aprotinin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (140 mg primed in ECC pump, continuous IV perfusion at 70 mg/h)
Trial: 26498428
Drug: Constant-current (CC)
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant-current (CC) stimulation
Trial: 26498428
Drug: Mixed implants
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed implants (CC after CV replacement)
Trial: 30314962
Drug: Treatment-as-usual (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (control group)
Trial: 18831859
Drug: Loratadine, 10
RxNorm normalized name: Loratadine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine, 10 mg, once daily
Trial: 12146000
Drug: Exemestane 0.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 0.5-50 mg/day after breakfast for 7 days
Trial: 1839442
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg once daily)
Trial: 27797396
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg
Trial: 107450
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg
Trial: 24093711
Drug: Local tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local tenoxicam injection (1 mL of tenoxicam 20 mg/2 mL and 1 mL of 2% lidocaine)
Trial: 24093711
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 mL containing 40 mg of methylprednisolone acetate and 1 mL of 2% lidocaine)
Trial: 19462320
Drug: Mare's milk
RxNorm normalized name: Mare's milk protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mare's milk (250 ml daily for 16 weeks)
Trial: 15257848
Drug: Heart disease
RxNorm normalized name: BRACELET,MEDICAL ALERT HEART DISEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart disease prevention program (12 weekly sessions on lifestyle change and goal setting)
Trial: 8031164
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 400 mg of UFT orally for 7 days preoperatively, bolus 20 mg of MMC on the day of operation, bolus 10 mg of MMC the day after operation, followed by 800 mg of FT intravenously for 2 weeks and daily oral administration of 400 mg of UFT thereafter
Trial: 8031164
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Bolus 20 mg of MMC on the day of surgery, bolus 10 mg the day after surgery, and 400 mg of UFT orally daily from 2 weeks after surgery
Trial: 3136064
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tocainide
Trial: 21476961
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target of < 100 mg/dl
Trial: 21476961
Drug: LDL-C target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C target of < 130 mg/dl
Trial: 27837658
Drug: OLZ (olanzapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLZ (olanzapine monotherapy)
Trial: 7901248
Drug: Topical diphenylcyclopropenone
RxNorm normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diphenylcyclopropenone (DPCP)
Trial: 3306128
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose Methotrexate
Trial: 31820537
Drug: Sacubitril/valsartan (97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (97/103 mg b.i.d.)
Trial: 28553078
Drug: Metformin extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin extended release (XR)
Trial: 23046107
Drug: Progestin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin (5 mg medroxyprogesterone acetate/day for 30 days)
Trial: 23046107
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one pill/day for 30 days)
Trial: 20675975
Drug: MS-sNT (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-sNT (morphine sulfate and naltrexone hydrochloride extended release capsules)
Trial: 20393176
Drug: Alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alglucosidase alfa (20 mg/kg biweekly for 78 weeks)
Trial: 16392706
Drug: Rice diet
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice diet (protein, 6.3 g; fat, 0.9 g; CHO, 79.3 g; energy, 368 kcal)
Trial: 16392706
Drug: Bread diet
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bread diet (protein, 15.7 g; fat, 5.8 g; CHO, 79.2 g; energy, 450 kcal)
Trial: 2853961
Drug: terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 60 mg orally
Trial: 2853961
Drug: enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 5 mg orally 3 h before
Trial: 29883070
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (CONT group; n = 20)
Trial: 30618475
Drug: Cariprazine (1.5-4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine (1.5-4.5 mg/day)
Trial: 1090417
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate cream
Trial: 11549974
Drug: rizatriptan 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rizatriptan 10‐mg wafer
Trial: 2906290
Drug: Oral yohimbine
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral yohimbine (0.2 mg kg-1)
Trial: 19930765
Drug: Berry purée
RxNorm normalized name: PEA PUREE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berry purée with 35 g sucrose
Trial: 15933563
Drug: Amoxicillin/clavulanate (90/6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (90/6.4 mg/kg/d in 2 divided doses for 10 days)
Trial: 15933563
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg for 1 day followed by 5 mg/kg/d for 4 days)
Trial: 10747531
Drug: Control (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (blood pressure, weight, and pulse measured at six weekly intervals)
Trial: 2096499
Drug: Chloroquine 25
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 25 mg/kg body weight over 3 days
Trial: 2096499
Drug: Mefloquine 25
RxNorm normalized name: mefloquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 25 mg/kg body weight single dose
Trial: 30337172
Drug: Inactivated monovalent
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated monovalent influenza A/H1N1 vaccine (IIV), two doses administered three weeks apart
Trial: 10590183
Drug: Heparin-treated patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-treated patients
Trial: 8168235
Drug: pyquiton at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyquiton at a single dose of 2.5 mg/kg
Trial: 8168235
Drug: pyquiton (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyquiton (not specified dosage)